Latest On ContraFect Corporation (CFRX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-15 22:13 EST | News | Contrafect GAAP EPS of -$0.69 | N/A |  |
| 2023-03-31 18:38 EST | News | Contrafect GAAP EPS of -$16.14 | N/A | |
| 2023-02-28 18:15 EST | News | ContraFect prices $10M in stock offering and concurrent private placement | N/A | |
| 2022-12-13 21:24 EST | News | ContraFect to purchase ~$7M of shares | N/A | |
| 2022-11-15 00:08 EST | News | Contrafect GAAP EPS of -$0.43 misses by $0.20 | N/A | |
| 2022-08-15 12:51 EST | News | Contrafect GAAP EPS of -$0.46 misses by $0.13 | N/A | |
| 2022-07-14 04:17 EST | News | ContraFect sinks ~76% as data safety board recommends ending co's DISRUPT trial | N/A | |
| 2022-05-16 10:01 EST | News | Contrafect GAAP EPS of -$0.51 | N/A | |
| 2022-03-25 17:36 EST | News | Contrafect GAAP EPS of -$0.11 beats by $0.19 | N/A | |
| 2022-02-25 06:02 EST | News | ContraFect (CFRX) Investor Presentation - Slideshow | N/A | |
| 2021-11-15 22:36 EST | News | Contrafect EPS beats by $0.15 | N/A | |
| 2021-09-17 16:24 EST | News | ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market | N/A | |
| 2021-08-13 10:53 EST | News | Contrafect EPS beats by $0.14 | N/A | |
| 2021-03-30 22:59 EST | News | Contrafect EPS beats by $0.08 | N/A | |
| 2021-03-18 16:13 EST | News | ContraFect trades lower on pricing public offering | N/A | |
| 2021-03-17 20:26 EST | News | ContraFect under pressure on stock offering | N/A | |
| 2021-03-17 12:21 EST | Analyst Rating | The Analyst Target Price has increased from $17.75 to $18.3. | Buy | |
| 2021-03-16 20:26 EST | Earnings Estimate | An EPS average of -$0.12 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2021-03-12 01:18 EST | News | ContraFect receives $86.8M in BARDA contract award | N/A | |
| 2021-03-11 04:39 EST | News | ContraFect And Its Narrowed Phase 3 Approach | N/A | |
| 2020-12-24 15:31 EST | Analyst Rating | The Analyst Target Price has increased from $17.2 to $17.75. | Buy | |
| 2020-12-13 03:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-25 11:36 EST | Analyst Rating | The Analyst Target Price has increased from $15.67 to $17.2. | Buy | |
| 2020-11-18 03:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 23:39 EST | News | Contrafect EPS beats by $0.16 | N/A | |
| 2020-11-07 15:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-01 17:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-19 08:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 04:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-26 10:06 EST | News | ContraFect secures research funding from Cystic Fibrosis Foundation | N/A | |
| 2020-08-17 00:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-16 00:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-15 19:39 EST | News | Mixed shelf roundup - healthcare | N/A | |
| 2020-08-14 15:33 EST | News | Contrafect EPS misses by $0.55 | N/A | |
| 2020-07-31 00:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 16:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-20 11:39 EST | News | ContraFect secures funding of up to $18.9M | N/A | |
| 2020-07-10 08:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 08:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-10 08:20 EST | Analyst Rating | The Analyst Target Price has decreased from $16.4 to $15.67. | Neutral | |
| 2020-06-09 22:07 EST | News | ContraFect +2.6% as Cantor Fitzgerald starts at Overweight | N/A | |
| 2020-06-09 08:18 EST | Analyst Rating | The Analyst Target Price has decreased from $16.75 to $16.4. | Neutral | |
| 2020-06-02 08:21 EST | Earnings Estimate | An EPS average of -$0.57 is estimated for the quarter ending on September 30, 2020. | Sell | |
| 2020-06-02 08:21 EST | Analyst Rating | The Analyst Target Price has decreased from $17.33 to $16.75. | Neutral | |
| 2020-05-31 16:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-25 10:35 EST | News | ContraFect prices ~$52.5M public offering | N/A | |
| 2020-05-20 20:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-17 17:19 EST | News | Contrafect EPS beats by $0.10 | N/A | |
| 2020-05-03 08:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-11 07:47 EST | News | ContraFect +14% premarket on BTD tag for exebacase | N/A | |
About ContraFect Corporation (CFRX):
ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. ContraFect Corporation has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. The company also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
General
- Name ContraFect Corporation
- Symbol CFRX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 24
- Last Split Factor1:10
- Last Split Date2020-02-04
- Fiscal Year EndDecember
- IPO Date2014-07-29
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.contrafect.com
View More
Valuation
- Trailing PE 18.8
- Price/Book (Most Recent Quarter) 7.94
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.34
- Return on Assets -48%
- Return on Equity -284%
- Earnings Per Share $0.44
- Revenue Per Share $0
- Gross Profit -1698063
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 142.67 million
- EBITDA -30248390
- Analyst Target Price $18.3
- Book Value Per Share $0.66
View More
Share Statistics
- Shares Outstanding 27.81 million
- Shares Float 20.89 million
- % Held by Insiders 876%
- % Held by Institutions 62.53%
- Shares Short 2.68 million
- Shares Short Prior Month 2.42 million
- Short Ratio 8.87
- Short % of Float 11%
- Short % of Shares Outstanding 10%
View More
Technicals
- Beta 0.97
- 52 Week High $8.45
- 52 Week Low $4.4
- 50 Day Moving Average 5.65
- 200 Day Moving Average 5.45
View More
Dividends
- Dividend Date 2020-02-04
- ExDividend Date N/A
- Dividend Yield 0%
View More
ContraFect Corporation (CFRX) Dividend Calendar:
CFRX's last dividend payment was made to shareholders on February 4, 2020.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
ContraFect Corporation (CFRX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-13 | $N/A | $0.12 | -$0.35 | 134.29% |
| 2020-06-30 | 2020-08-14 | $N/A | -$0.88 | -$0.33 | -164.66% |
| 2020-03-31 | 2020-05-15 | $N/A | -$0.49 | -$0.59 | 17.41% |
| 2019-12-31 | 2020-03-18 | $N/A | -$1.11 | -$0.79 | -40.95% |
| 2019-09-30 | 2019-11-12 | $N/A | -$0.70 | -$0.72 | 2.78% |
| 2019-06-30 | 2019-08-09 | $N/A | -$1.10 | -$0.86 | -27.91% |
| 2019-03-31 | 2019-05-10 | $N/A | $1.50 | -$1.03 | 246.34% |
| 2018-12-31 | 2019-03-14 | $N/A | $0.70 | -$0.96 | 172.92% |
| 2018-09-30 | 2018-11-08 | $N/A | -$0.60 | -$0.97 | 37.93% |
| 2018-06-30 | 2018-08-09 | $N/A | -$2.70 | -$0.98 | -174.59% |
| 2018-03-31 | 2018-05-10 | $N/A | -$2.60 | -$0.90 | -188.89% |
| 2017-12-31 | 2018-03-15 | $N/A | -$0.60 | -$1.00 | 40% |
| 2017-09-30 | 2017-11-09 | $N/A | -$0.20 | -$1.15 | 82.61% |
| 2017-06-30 | 2017-08-09 | $N/A | -$0.70 | -$1.63 | 57.14% |
| 2017-03-31 | 2017-05-08 | $N/A | -$1.50 | -$1.65 | 9.09% |
| 2016-12-31 | 2017-03-15 | $N/A | $0.10 | -$1.98 | 105.06% |
| 2016-09-30 | 2016-11-09 | $N/A | -$2.80 | -$2.00 | -40% |
| 2016-06-30 | 2016-08-09 | $N/A | -$3.50 | -$2.58 | -35.92% |
| 2016-03-31 | 2016-05-10 | $N/A | -$3.20 | -$2.40 | -33.33% |
| 2015-12-31 | 2016-03-15 | $N/A | -$2.80 | -$2.23 | -25.38% |
| 2015-09-30 | 2015-11-12 | $N/A | -$0.22 | -$0.22 | 0% |
| 2015-06-30 | 2015-08-13 | $N/A | -$0.33 | -$0.23 | -43.48% |
| 2015-03-31 | 2015-05-15 | $N/A | -$0.24 | -$0.22 | -9.09% |
| 2014-12-31 | 2015-03-26 | $N/A | -$0.53 | -$0.18 | -194.44% |
| 2014-09-30 | 2014-11-14 | $N/A | -$1.22 | -$0.21 | -480.95% |
ContraFect Corporation (CFRX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
ContraFect Corporation (CFRX) Chart:
ContraFect Corporation (CFRX) News:
Below you will find a list of latest news for ContraFect Corporation (CFRX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
ContraFect Corporation (CFRX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest CFRX Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:50 PM EST | 29 | $3.3 |
| Jun 13, 2022 7:51 PM EST | 200 | $3.28 |
| Jun 13, 2022 7:53 PM EST | 100 | $3.28 |
| Jun 13, 2022 7:58 PM EST | 100 | $3.3 |
| Jun 13, 2022 7:58 PM EST | 100 | $3.31 |
ContraFect Corporation (CFRX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120037291/0001209191-20-037291-index.htm |
| 2018-12-21 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1478069/000000000018039004/0000000000-18-039004-index.htm |
| 2020-08-21 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1478069/000000000020007850/0000000000-20-007850-index.htm |
| 2019-12-16 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000007800319000086/0000078003-19-000086-index.htm |
| 2018-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000090266418000995/0000902664-18-000995-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000090266419000937/0000902664-19-000937-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000090266420000968/0000902664-20-000968-index.htm |
| 2018-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000091957418001224/0000919574-18-001224-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000092189519000481/0000921895-19-000481-index.htm |
| 2020-10-20 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000092189520002651/0000921895-20-002651-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000092963818000290/0000929638-18-000290-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000092963819000266/0000929638-19-000266-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000101359418000132/0001013594-18-000132-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000101359419000157/0001013594-19-000157-index.htm |
| 2020-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000110465920015213/0001104659-20-015213-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000110465920021721/0001104659-20-021721-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000110465920021761/0001104659-20-021761-index.htm |
| 2020-05-29 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000110465920067428/0001104659-20-067428-index.htm |
| 2018-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000114420418007978/0001144204-18-007978-index.htm |
| 2018-03-21 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000114420418016188/0001144204-18-016188-index.htm |
| 2018-12-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000114420418063384/0001144204-18-063384-index.htm |
| 2018-12-06 | 3/A | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000114420418063387/0001144204-18-063387-index.htm |
| 2018-12-06 | 3/A | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000114420418063391/0001144204-18-063391-index.htm |
| 2018-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000114420418063392/0001144204-18-063392-index.htm |
| 2018-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000114420418063394/0001144204-18-063394-index.htm |
| 2019-01-22 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000114420419002157/0001144204-19-002157-index.htm |
| 2019-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000114420419005979/0001144204-19-005979-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000114420419007233/0001144204-19-007233-index.htm |
| 2018-03-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312518084147/0001193125-18-084147-index.htm |
| 2018-03-15 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1478069/000119312518084172/0001193125-18-084172-index.htm |
| 2018-03-21 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1478069/000119312518090605/0001193125-18-090605-index.htm |
| 2018-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312518157517/0001193125-18-157517-index.htm |
| 2018-05-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312518159290/0001193125-18-159290-index.htm |
| 2018-05-10 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1478069/000119312518159336/0001193125-18-159336-index.htm |
| 2018-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312518159359/0001193125-18-159359-index.htm |
| 2018-05-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312518178467/0001193125-18-178467-index.htm |
| 2018-07-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312518227977/0001193125-18-227977-index.htm |
| 2018-07-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312518227978/0001193125-18-227978-index.htm |
| 2018-07-27 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312518229715/0001193125-18-229715-index.htm |
| 2018-07-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312518233147/0001193125-18-233147-index.htm |
| 2018-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312518244312/0001193125-18-244312-index.htm |
| 2018-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312518244471/0001193125-18-244471-index.htm |
| 2018-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312518322560/0001193125-18-322560-index.htm |
| 2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312518322649/0001193125-18-322649-index.htm |
| 2018-11-30 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1478069/000119312518339854/0001193125-18-339854-index.htm |
| 2018-12-11 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1478069/000119312518346962/0001193125-18-346962-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519003861/0001193125-19-003861-index.htm |
| 2019-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519051975/0001193125-19-051975-index.htm |
| 2019-03-14 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1478069/000119312519074982/0001193125-19-074982-index.htm |
| 2019-03-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519075008/0001193125-19-075008-index.htm |
| 2019-03-20 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1478069/000119312519080801/0001193125-19-080801-index.htm |
| 2019-04-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519095743/0001193125-19-095743-index.htm |
| 2019-04-02 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1478069/000119312519095752/0001193125-19-095752-index.htm |
| 2019-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519143073/0001193125-19-143073-index.htm |
| 2019-05-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519144242/0001193125-19-144242-index.htm |
| 2019-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312519144267/0001193125-19-144267-index.htm |
| 2019-05-13 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1478069/000119312519145526/0001193125-19-145526-index.htm |
| 2019-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519159707/0001193125-19-159707-index.htm |
| 2019-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519218003/0001193125-19-218003-index.htm |
| 2019-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312519218012/0001193125-19-218012-index.htm |
| 2019-08-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519226893/0001193125-19-226893-index.htm |
| 2019-10-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519260859/0001193125-19-260859-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312519290046/0001193125-19-290046-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519290079/0001193125-19-290079-index.htm |
| 2019-12-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519309358/0001193125-19-309358-index.htm |
| 2019-12-09 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312519309370/0001193125-19-309370-index.htm |
| 2019-12-09 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1478069/000119312519309380/0001193125-19-309380-index.htm |
| 2019-12-10 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1478069/000119312519310271/0001193125-19-310271-index.htm |
| 2019-12-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312519311552/0001193125-19-311552-index.htm |
| 2019-12-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519312836/0001193125-19-312836-index.htm |
| 2019-12-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312519317487/0001193125-19-317487-index.htm |
| 2019-12-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312519319135/0001193125-19-319135-index.htm |
| 2019-12-27 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1478069/000119312519325067/0001193125-19-325067-index.htm |
| 2020-01-06 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1478069/000119312520002260/0001193125-20-002260-index.htm |
| 2020-02-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312520023443/0001193125-20-023443-index.htm |
| 2020-02-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312520044818/0001193125-20-044818-index.htm |
| 2020-02-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312520046635/0001193125-20-046635-index.htm |
| 2020-03-18 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1478069/000119312520077242/0001193125-20-077242-index.htm |
| 2020-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312520077259/0001193125-20-077259-index.htm |
| 2020-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312520141669/0001193125-20-141669-index.htm |
| 2020-05-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312520144117/0001193125-20-144117-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312520144128/0001193125-20-144128-index.htm |
| 2020-05-21 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312520148831/0001193125-20-148831-index.htm |
| 2020-05-21 | S-3MEF | Registration adding securities to prior Form S-3 registration [Rule 462(b)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312520148980/0001193125-20-148980-index.htm |
| 2020-05-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312520151590/0001193125-20-151590-index.htm |
| 2020-05-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312520153110/0001193125-20-153110-index.htm |
| 2020-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312520171410/0001193125-20-171410-index.htm |
| 2020-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1478069/000119312520220373/0001193125-20-220373-index.htm |
| 2020-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1478069/000119312520220403/0001193125-20-220403-index.htm |
| 2020-08-14 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1478069/000119312520220466/0001193125-20-220466-index.htm |
| 2020-08-14 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1478069/000119312520220578/0001193125-20-220578-index.htm |
| 2020-08-27 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1478069/000119312520233141/0001193125-20-233141-index.htm |
| 2018-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919118029225/0001209191-18-029225-index.htm |
| 2018-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919118029226/0001209191-18-029226-index.htm |
| 2018-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919118029229/0001209191-18-029229-index.htm |
| 2018-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919118029230/0001209191-18-029230-index.htm |
| 2018-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919118029233/0001209191-18-029233-index.htm |
| 2018-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919118029248/0001209191-18-029248-index.htm |
| 2019-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119008052/0001209191-19-008052-index.htm |
| 2019-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119008054/0001209191-19-008054-index.htm |
| 2019-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119008057/0001209191-19-008057-index.htm |
| 2019-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119008061/0001209191-19-008061-index.htm |
| 2019-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119008069/0001209191-19-008069-index.htm |
| 2019-04-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119023588/0001209191-19-023588-index.htm |
| 2019-05-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119033181/0001209191-19-033181-index.htm |
| 2019-05-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119033186/0001209191-19-033186-index.htm |
| 2019-05-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119033192/0001209191-19-033192-index.htm |
| 2019-05-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119033200/0001209191-19-033200-index.htm |
| 2019-05-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119033205/0001209191-19-033205-index.htm |
| 2019-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119036565/0001209191-19-036565-index.htm |
| 2019-08-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119046157/0001209191-19-046157-index.htm |
| 2019-08-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119046163/0001209191-19-046163-index.htm |
| 2019-08-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119046165/0001209191-19-046165-index.htm |
| 2019-08-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119046175/0001209191-19-046175-index.htm |
| 2019-08-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119046195/0001209191-19-046195-index.htm |
| 2019-12-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119060535/0001209191-19-060535-index.htm |
| 2019-12-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119060537/0001209191-19-060537-index.htm |
| 2019-12-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919119060539/0001209191-19-060539-index.htm |
| 2020-02-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120011627/0001209191-20-011627-index.htm |
| 2020-02-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120011636/0001209191-20-011636-index.htm |
| 2020-02-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120011643/0001209191-20-011643-index.htm |
| 2020-02-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120011646/0001209191-20-011646-index.htm |
| 2020-02-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120012174/0001209191-20-012174-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120030106/0001209191-20-030106-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120030108/0001209191-20-030108-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120030110/0001209191-20-030110-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120030117/0001209191-20-030117-index.htm |
| 2020-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120030121/0001209191-20-030121-index.htm |
| 2020-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120036644/0001209191-20-036644-index.htm |
| 2020-06-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120037261/0001209191-20-037261-index.htm |
| 2020-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1478069/000120919120037291/0001209191-20-037291-index.htm |
| 2020-06-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000138713120005404/0001387131-20-005404-index.htm |
| 2020-03-30 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1478069/000156459020014233/0001564590-20-014233-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000162363218000211/0001623632-18-000211-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000162363219000242/0001623632-19-000242-index.htm |
| 2019-04-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000162363219000472/0001623632-19-000472-index.htm |
| 2020-01-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1478069/000162363220000022/0001623632-20-000022-index.htm |
| 2018-12-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1478069/999999999518003128/9999999995-18-003128-index.htm |
| 2020-08-31 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1478069/999999999520002320/9999999995-20-002320-index.htm |
ContraFect Corporation (CFRX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of ContraFect Corporation (CFRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 876%Institutional Ownership: 6253%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-12-13 | Michael Messinger | Chief Financial Officer | Buy | 5,000.00 | 0.37 | 1,850.00 | 19,091.00 | https://www.sec.gov/Archives/edgar/data/1478069/000120919119060539/0001209191-19-060539-index.htm |
| 2019-12-13 | David N. Low | Director | Buy | 300,000.00 | 0.43 | 129,000.00 | 370,550.00 | https://www.sec.gov/Archives/edgar/data/1478069/000120919119060535/0001209191-19-060535-index.htm |
| 2019-12-13 | Cary Sucoff | Director | Buy | 50,000.00 | 0.39 | 19,500.00 | 62,000.00 | https://www.sec.gov/Archives/edgar/data/1478069/000120919119060537/0001209191-19-060537-index.htm |
| 2018-12-04 | Fosun Industrial Co., Ltd | 10% Share Holder | Sell | 600,000.00 | 2.04 | 1,224,000.00 | 7,900,000.00 | https://www.sec.gov/Archives/edgar/data/1478069/000114420418063394/0001144204-18-063394-index.htm |
| 2018-12-04 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% Share Holder | Sell | 600,000.00 | 2.04 | 1,224,000.00 | 7,900,000.00 | https://www.sec.gov/Archives/edgar/data/1478069/000114420418063392/0001144204-18-063392-index.htm |